Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347, SHE: 300347), China’s largest clinical contract research organization (CRO), released its unaudited interim results for the six months ended 30 June 2026. Revenue rose 14.1% year‑on‑year to RMB3,707.6 million, and adjusted profit excluding extraordinary gains/losses jumped 31.8% to RMB277.7 million — but reported net profit swung to a loss of RMB413.2 million attributable to owners (1H25: +RMB383.3 m), driven by RMB443.3 million of non‑cash fair‑value losses on the Group’s listed equity portfolio amid Q2 2026 market volatility. The Board declared no interim dividend.
Contents
Financial Highlights – 1H 2026 vs. 1H 2025
| Metric | 1H 2026 | 1H 2025 | Change |
|---|---|---|---|
| Revenue | RMB3,707.6 m | RMB3,250.4 m | +14.1 % |
| – Clinical Trial Services (CTS) | RMB1,773.4 m | RMB1,469.5 m | +20.7 % |
| – Clinical Research & Lab Services (CRLS) | RMB1,934.2 m | RMB1,780.9 m | +8.6 % |
| Gross Profit | RMB1,020.5 m | RMB978.0 m | +4.3 % |
| Gross Margin | 27.5 % | 30.1 % | −2.6 ppt |
| Net Profit Attributable to Owners | RMB(413.2) m | RMB383.3 m | −207.8 % |
| Adj. Net Profit (excl. extraordinary items, non‑CASBE) | RMB277.7 m | RMB210.7 m | +31.8 % |
| Basic & Diluted EPS | RMB(0.48) | RMB0.45 | −206.7 % |
| Operating Cash Flow | RMB425.8 m | RMB408.6 m | +4.2 % |
| Interim Dividend | None | None | – |
Geographic split: PRC revenue grew 24.0 % to RMB2,106.1 million; overseas revenue rose 3.2 % to RMB1,601.5 million, dampened by continued RMB appreciation against the USD.
What Drove the Reported Loss
- Fair‑Value Swings: A RMB443.3 million loss on changes in fair value (1H25: RMB89.6 m loss), chiefly from lower share prices in the listed equity portfolio during Q2 2026 — including a RMB719.3 million mark‑to‑market loss on the Group’s stake in PegBio (2565.HK), partially offset by a RMB108.4 million gain on unlisted equities following up‑round financings.
- Investment Income Reversal: Investment income swung to a RMB2.4 million loss from a RMB233.0 million gain, as share of profit from associates fell to RMB21.7 m (1H25: RMB166.4 m) and disposal of non‑current financial assets generated a RMB46.1 m loss.
- Tax Anomaly: Because the fair‑value losses are non‑taxable, taxable profit remained positive: income tax expense rose 31.8 % to RMB105.3 million despite a pre‑tax loss of RMB80.2 million, rendering the effective tax rate not meaningful.
- Core Operations Intact: Excluding these items, the underlying business strengthened — adjusted net margin widened to 7.5 % from 6.5 %, operating cash inflow grew on a 21.7 % increase in collections, and trade receivables fell 5.3 % to RMB1,331.7 million.
Segment Performance & Cost Base
- CTS (+20.7 %): Domestic innovative‑drug clinical operations resumed solid growth as legacy low‑price projects cleared; average unit prices of new bookings returned to growth in 1H 2026. Segment gross margin eased to 21.1 % (1H25: 22.8 %) on prior low‑price order execution and resumed team expansion.
- CRLS (+8.6 %): SMO revenue growth stayed strong on multinational orders (3,094 ongoing SMO projects; 4,000+ CRCs across 146 cities); central lab accelerated on recovering domestic testing demand; Frontage (US lab recovery + acquisition of Teddy Clinical Research Laboratory) drove laboratory services growth. Segment gross margin: 33.4 % (1H25: 36.1 %).
- Opex: R&D expenses +9.8 % to RMB139.4 million (AI/digital investment); selling & marketing +1.7 % to RMB109.7 m; administrative −0.6 % to RMB353.2 m.
- Balance Sheet: Cash at bank RMB2,099.3 million (YE2025: RMB1,777.5 m); borrowings RMB1,874.8 m; gearing ratio 8.1 % (YE2025: 4.6 %); unutilized bank facilities of RMB5,575.1 m; contract liabilities +25.5 % to RMB1,354.7 million on higher customer prepayments — a forward revenue indicator.
Operating Metrics & Bookings Momentum
- Market Leadership: Per Frost & Sullivan, Tigermed’s share of China’s clinical CRO market reached 10.9 % in 2025 (2024: 10.6 %) — the only China‑based provider in the global top 10. In 1H 2026 it served 31 of the 38 NMPA‑approved Class 1 new drugs and has cumulatively supported 62 % of all Class 1 new drugs marketed in China over 20 years.
- Bookings: Net new bookings accelerated YoY and new‑booking average unit prices returned to growth; contract liabilities +25.5 % corroborate strengthening demand.
- Project Portfolio (30 Jun 2026): 667 ongoing drug clinical projects (YE2025: 663), including 55 MRCTs (YE2025: 48) and 209 overseas single‑region trials; 28 new US FDA IND projects and 21 FDA clinical approvals in 1H 2026.
- Global Footprint: 11,984 employees across 43 countries (2,019 overseas). North America: 59 ongoing trials (+45 % YoY), 200+ staff, 46 new contracts; Australia/NZ: new orders ~+100 % YoY, new New Zealand subsidiary; new Malaysia office; EMEA passed 10+ NMPA/FDA/EMA inspections with no critical findings; 420+ staff in South Korea. New global HQ Tigermed Park completed in Hangzhou (March 2026).
- AI & DCT: Enterprise AI agent platform completed; intelligent medical‑writing tools cut writing labor 40–60 %; AI site selection compresses cycles from 2–4 weeks to ~1 hour; new DCT‑element trial orders exceeded RMB300 million.
- Shareholder Returns: Under the RMB500 million–RMB1 billion buyback plan (approved 13 May 2026), Tigermed repurchased 20,963,478 A shares (2.4 % of share capital) at an average RMB39.32 for RMB824.3 million during the period; 26.8 million treasury A shares held at period‑end for equity incentive/ESOP use or cancellation.
Industry Tailwinds & Outlook
- China Innovation Boom: NMPA approved 38 Class 1 new drugs in 1H 2026; CDE announced 1,313 Phase I–III innovative‑drug trials (1H25: 1,012); IND approvals rose 27 % YoY to 1,908. Chinese studies captured 12 of 63 LBAs at ASCO 2026 (~one‑fifth of the total).
- Licensing Wave Fuels CRO Demand: Outbound license‑out upfront payments hit USD4.97 billion (+68.4 % YoY) with potential total deal value of USD99.89 billion (+42.0 %); biopharma PE/VC financing surged 189 % to USD4.26 billion — repairing client cash flows and supporting long‑term clinical demand.
- Consolidation: Supply‑side CRO consolidation continued, shifting the industry toward benign competition and favoring scaled, globally capable players like Tigermed.
- Strategy: New strategic cooperation agreements with Hisun, Insilico Medicine, 3SBio and a leading European multinational; management will keep investing in AI, expand overseas teams (incl. potential M&A), deepen multinational client penetration, and target sustainable performance growth in 2H 2026. MSCI ESG rating upgraded to AAA.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Tigermed’s bookings trajectory, revenue growth, margin recovery, AI commercialization, overseas expansion, capital‑return plans, and exposure to equity‑market movements. Actual results may differ due to risks including industry pricing competition, FX fluctuation, regulatory changes, client financing conditions, portfolio valuation volatility, and execution of strategic initiatives. Interim figures are unaudited and prepared under CASBE; the adjusted profit measure is non‑CASBE.-Fineline Info & Tech
